Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
$8.37
$8.37
$2.66
$8.55
$401.26M0.522.97 million shsN/A
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
$2.99
+5.3%
$3.10
$1.75
$6.75
$8.10M1.842,951 shs586 shs
NuCana plc stock logo
NCNA
NuCana
$3.76
-3.8%
$6.23
$3.40
$23.75
$7.78M1.0357,208 shs328,945 shs
Aratana Therapeutics Inc stock logo
PETX
Aratana Therapeutics
$4.92
$4.92
$3.30
$7.16
$241.08M1.41.03 million shsN/A
Urovant Sciences Ltd. stock logo
UROV
Urovant Sciences
$16.24
$16.23
$7.15
$16.26
$531.75M2.36114,469 shsN/A
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
0.00%-2.41%-13.94%+1.43%-52.07%
NuCana plc stock logo
NCNA
NuCana
+0.77%-2.49%-32.79%-46.58%-77.66%
Aratana Therapeutics Inc stock logo
PETX
Aratana Therapeutics
0.00%0.00%0.00%0.00%0.00%
Urovant Sciences Ltd. stock logo
UROV
Urovant Sciences
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
NuCana plc stock logo
NCNA
NuCana
2.9459 of 5 stars
3.55.00.00.00.02.51.3
Aratana Therapeutics Inc stock logo
PETX
Aratana Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Urovant Sciences Ltd. stock logo
UROV
Urovant Sciences
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
N/AN/AN/AN/A
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
N/AN/AN/AN/A
NuCana plc stock logo
NCNA
NuCana
3.00
Buy$125.003,224.47% Upside
Aratana Therapeutics Inc stock logo
PETX
Aratana Therapeutics
N/AN/AN/AN/A
Urovant Sciences Ltd. stock logo
UROV
Urovant Sciences
N/AN/AN/AN/A

Current Analyst Ratings

Latest PETX, UROV, CYCN, NCNA, and CNCE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/1/2024
NuCana plc stock logo
NCNA
NuCana
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$100.00
(Data available from 5/8/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
$32.58M12.32N/AN/A$3.24 per share2.58
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
$1.62M5.00N/AN/A$4.62 per share0.65
NuCana plc stock logo
NCNA
NuCana
N/AN/AN/AN/A$8.85 per shareN/A
Aratana Therapeutics Inc stock logo
PETX
Aratana Therapeutics
$35.41M6.81N/AN/A$2.07 per share2.38
Urovant Sciences Ltd. stock logo
UROV
Urovant Sciences
N/AN/AN/AN/A($1.90) per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
-$80.05M-$3.21N/AN/AN/AN/A-109.43%-76.65%N/A
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
-$5.26M-$5.51N/AN/AN/A-111.79%-74.10%7/26/2024 (Estimated)
NuCana plc stock logo
NCNA
NuCana
-$34.37M-$16.00N/AN/AN/AN/A-115.42%-72.84%5/15/2024 (Estimated)
Aratana Therapeutics Inc stock logo
PETX
Aratana Therapeutics
-$14.72M-$0.32N/AN/AN/A-33.47%-12.99%-10.82%N/A
Urovant Sciences Ltd. stock logo
UROV
Urovant Sciences
-$146.74M-$4.71N/AN/AN/AN/AN/A-162.90%N/A

Latest PETX, UROV, CYCN, NCNA, and CNCE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/20/2024Q4 2023
NuCana plc stock logo
NCNA
NuCana
-$3.25-$4.25-$1.00-$0.17N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
N/AN/AN/AN/AN/A
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
N/AN/AN/AN/AN/A
NuCana plc stock logo
NCNA
NuCana
N/AN/AN/AN/AN/A
Aratana Therapeutics Inc stock logo
PETX
Aratana Therapeutics
N/AN/AN/AN/AN/A
Urovant Sciences Ltd. stock logo
UROV
Urovant Sciences
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
N/A
9.03
9.03
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
N/A
3.85
3.85
NuCana plc stock logo
NCNA
NuCana
N/A
1.97
1.97
Aratana Therapeutics Inc stock logo
PETX
Aratana Therapeutics
N/A
6.66
5.32
Urovant Sciences Ltd. stock logo
UROV
Urovant Sciences
N/A
2.91
2.91

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
70.63%
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
75.62%
NuCana plc stock logo
NCNA
NuCana
44.00%
Aratana Therapeutics Inc stock logo
PETX
Aratana Therapeutics
65.00%
Urovant Sciences Ltd. stock logo
UROV
Urovant Sciences
18.44%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
6447.94 million42.51 millionOptionable
Cyclerion Therapeutics, Inc. stock logo
CYCN
Cyclerion Therapeutics
12.71 million2.36 millionNo Data
NuCana plc stock logo
NCNA
NuCana
252.07 million1.43 millionNot Optionable
Aratana Therapeutics Inc stock logo
PETX
Aratana Therapeutics
8349.00 millionN/AOptionable
Urovant Sciences Ltd. stock logo
UROV
Urovant Sciences
7032.74 millionN/ANot Optionable

PETX, UROV, CYCN, NCNA, and CNCE Headlines

SourceHeadline
Pierre Fabre Laboratories receive positive CHMP opinion for OBGEMSA(vibegron) in overactive bladder syndromePierre Fabre Laboratories receive positive CHMP opinion for OBGEMSA(vibegron) in overactive bladder syndrome
finanznachrichten.de - April 26 at 1:33 PM
Pierre Fabre Laboratories receive positive CHMP opinion for OBGEMSA™(vibegron) in overactive bladder syndromePierre Fabre Laboratories receive positive CHMP opinion for OBGEMSA™(vibegron) in overactive bladder syndrome
finance.yahoo.com - April 26 at 1:33 PM
OC Drugmakers Cut Headcounts, Close OfficesOC Drugmakers Cut Headcounts, Close Offices
ocbj.com - April 22 at 7:23 PM
A2 Bio’s new CEO aims to grow platformA2 Bio’s new CEO aims to grow platform
pacbiztimes.com - April 8 at 6:15 AM
C-Suite Shuffle: A2 Bio, Bayer, BioNTech and MoreC-Suite Shuffle: A2 Bio, Bayer, BioNTech and More
biospace.com - March 27 at 2:46 AM
A2 Bio Appoints James Robinson as New Chief Executive Officer and Member of the Board of DirectorsA2 Bio Appoints James Robinson as New Chief Executive Officer and Member of the Board of Directors
finance.yahoo.com - March 26 at 3:06 AM
HEALTH BEHAVIOR AND NUTRITION SCIENCESHEALTH BEHAVIOR AND NUTRITION SCIENCES
udel.edu - February 17 at 2:30 PM
Bulletin Science and Security BoardBulletin Science and Security Board
thebulletin.org - February 15 at 3:32 PM
Secretary-General’s Guidance Note on Behavioural ScienceSecretary-General’s Guidance Note on Behavioural Science
un.org - February 5 at 9:35 AM
Marine Sciences & TechnologyMarine Sciences & Technology
uml.edu - January 7 at 12:52 PM
The 7 Best Science Kits for Kids and TeensThe 7 Best Science Kits for Kids and Teens
popularmechanics.com - December 22 at 12:32 AM
Careers in Computer ScienceCareers in Computer Science
mccormick.northwestern.edu - December 11 at 10:18 AM
PhD in Information SciencePhD in Information Science
drexel.edu - December 8 at 10:01 AM
Petauri™ Elects William Fleming and James Robinson to Its Board of DirectorsPetauri™ Elects William Fleming and James Robinson to Its Board of Directors
finance.yahoo.com - December 6 at 10:09 AM
Core Requirements & CoursesCore Requirements & Courses
bc.edu - December 1 at 1:25 PM
Inspiring Women in ScienceInspiring Women in Science
nature.com - November 28 at 10:11 AM
Develop your own cognitive toolkit.Develop your own cognitive toolkit.
miamioh.edu - November 17 at 9:55 AM
Benign Prostatic Hyperplasia Market Size in 7MM is expected to witness a major change in the study period 2019–2032, estimates DelveInsightBenign Prostatic Hyperplasia Market Size in 7MM is expected to witness a major change in the study period 2019–2032, estimates DelveInsight
medgadget.com - November 16 at 8:17 AM
PM360 Announces 2023 Trailblazer Award WinnersPM360 Announces 2023 Trailblazer Award Winners
finance.yahoo.com - October 4 at 8:59 AM
Heavy Drinking Not Tied to Lower Response to DAAs for Hepatitis CHeavy Drinking Not Tied to Lower Response to DAAs for Hepatitis C
medpagetoday.com - September 26 at 3:23 PM
Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of DirectorsEledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors
finance.yahoo.com - September 11 at 8:30 AM
Clinical and Translational Science InstituteClinical and Translational Science Institute
buffalo.edu - September 8 at 9:36 PM
MDxHealth CEO Bullish After Q2 Revenue BoostMDxHealth CEO Bullish After Q2 Revenue Boost
ocbj.com - September 5 at 8:49 PM
Windmill Model Science ProjectWindmill Model Science Project
education.com - August 15 at 1:51 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Concert Pharmaceuticals logo

Concert Pharmaceuticals

NASDAQ:CNCE
Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.
Cyclerion Therapeutics logo

Cyclerion Therapeutics

NASDAQ:CYCN
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
NuCana logo

NuCana

NASDAQ:NCNA
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.
Aratana Therapeutics logo

Aratana Therapeutics

NASDAQ:PETX
Aratana Therapeutics, Inc., a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States. Its product portfolio includes small molecule therapeutics and therapeutic candidates. The company markets NOCITA, a post-operative analgesia for cranial cruciate ligament surgery in dogs; ENTYCE for appetite stimulation in dogs; GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; and canine osteosarcoma vaccine, live listeria vector for the treatment of dogs diagnosed with osteosarcoma in the United States. It is also developing NOCITA, a bupivacaine liposome injectable suspension for post-operative pain in cats; AT-002, a specific formulation of capromorelin for use in cats; AT-018, an oral CRTH2 antagonist for the treatment of atopic dermatitis in dogs; AT-006, an anti-viral eprociclovir that is used for the treatment of feline herpes virus-induced ophthalmic conditions in cats; AT-016, allogeneic adipose-derived stem cells for dogs; and AT-019, an EP4 receptor antagonist therapeutic candidate with potential in pain, inflammation, and other indications. In addition, the company develops AT-008, a therapeutic candidate for treating canine lymphoma in dogs; and other therapeutics for dogs and cats in Europe. It has collaboration agreement with Elanco Animal Health, Inc. to develop, manufacture, and commercialize GRAPIPRANT products; Pacira Pharmaceuticals, Inc. to develop and commercialization of licensed animal health products for NOCITA; and AskAt Inc for the development and commercialization of compound AT-019. Aratana Therapeutics, Inc. was founded in 2010 and is headquartered in Leawood, Kansas.
Urovant Sciences logo

Urovant Sciences

NASDAQ:UROV
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions in the United States. The company's lead product candidate is vibegron, an oral small molecule beta-3 agonist for the treatment of overactive bladder (OAB), OAB in men with benign prostatic hyperplasia, and abdominal pain due to irritable bowel syndrome. It is also developing URO-902, a gene therapy for patients with OAB who have failed oral pharmacological therapy. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. Urovant Sciences Ltd. was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.